Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

By H. Boucher, G. Talbot, J. Bradley, J. Edwards, D. Gilbert, L. Rice, M. Scheld, B. Spellberg, J. Bartlett. Clinical Infectious Diseases, 2009

4,597 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Health, Toxicology and Mutagenesis, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/312d4368b8fa5667e88ec0c4de8a089632e6d891

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

In Health, Toxicology and Mutagenesis

In Molecular Medicine

Citations in the corpus

ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics (2024, neutral): “As a result, antimicrobial resistance is now a tangible threat to the day-to-day practice of medicine across the globe 3 .”
Antibiotic resistance in the environment: a link to the clinic? (2010, background): “These challenges have conspired to make new antibiotic discovery a low priority for the pharmaceutical industry despite a growing clinical need [2].”
Combating antimicrobial resistance: policy recommendations to save lives. (2011, background): “A combination of factors has resulted in a market failure of new antibiotic development, including the ability of antibiotics to cure most infections in just a few days, antibiotic resistance which makes the drugs less effective over time, and deliberate and essential measures taken by physicians to”
"Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. (2011, background): “This also explains the increasing antimicrobial resistance of nosocomial Gram-negative bacteria to extended-spectrum cephalosporin, a class of the newest andmost powerful antibiotics [4].”
Klebsiella pneumoniae: Going on the Offense with a Strong Defense (2016, background): “As a consequence of this antibiotic resistance, simple infections such as urinary tract infections (UTIs) have become recalcitrant to treatment, and more serious infections such as pneumonias and bacteremias have become increasingly life-threatening (6, 7).”
Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options (2017, background): “baumannii, Pseudomonas aeruginosa, and Enterobacter species) that effectively escape the effects of antibacterial drugs (Boucher et al., 2009).”
Bacteria Antibiotic Resistance: New Challenges and Opportunities for Implant-Associated Orthopaedic Infections (2017, background): “aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species have been identified as the so-called “ESKAPE” microorganisms which have caused significant morbidity and mortality.(5) In the U.”
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. (2013, background): “In our 2009 report, no antibacterial agent in development with a purely gramnegative spectrum had reached phase 2 of clinical study [2].”